bluuebunny/crossref_metadata_2025_split huggingface dataset:
Abstract P1-20-25: Impact of lumpectomy for diagnosis of primary tumor on disease free survival in women with operable breast cancer: An institutional audit
Authors: Nair Nita Sukumar , Hawaldar Rohini W , Chougle Quarratulain , Parmar Vani , Vanmali Vaibhav , Siddique Shabina , Devade Ashwini , Pandey Aarti , Joshi Shalaka , Gupta Sudeep , Badwe Rajendra A 
Published: March 2020

Abstract
Introduction: As a tertiary referral cancer centre, 20-30 % of patients seen in our breast clinic present after excision of the primary breast tumour without oncological principles maintained and no details on the excision margins. We evaluated the safety of excision biopsy (ExBx) as a diagnostic procedure by comparing the outcomes against patients who underwent definitive surgery after a core biopsy/FNAC (CxBx) for diagnosis.
Methods: We performed a retrospective audit of the case charts of women with breast cancer treated at our institution. We included women with operable breast cancer (OBC) who presented post ExBx of the primary tumour and those who were treatment naïve and operated after only a CxBx for diagnosis.
Results: Of the 1022 women included in the analysis, 551 underwent ExBx for primary diagnosis and 471 had CxBx prior to definitive breast surgery. The excision biopsy group were younger women (median age 44 years) with smaller tumours (median T size 2.5cm), lower HR ( hormone receptor) positive (58.3%) and less number were Her2+ve (16.7 %). In this group 17% received NACT, with 66.4% undergoing breast conservation surgery (BCS), and 37.6% node positive. While in the core biopsy group, the women were older women (median age 50 years) had larger tumours, median 3 cm, with 71.3% HR positive, 18.3% Her2 +ve, 72.8% underwent breast conservation surgery with 44.6 % node positive At a median follow up of 46 months, there was no difference in four year disease free survival (DFS) between ExBx group (83.8% versus 86.8%) and non-ExBx (HR=1.29,95%CI=0.93-1.79, p=0.13). When matched for T size, 699/1022 (69%) had T2 tumours and DFS in ExBx group was 80.7% in compared to 85.7% in non ExBx group. (HR=1.46, 95%CI=1.0-2.11, p=0.04). On multivariate cox regression, T size (HR=1.45,95%CI=1.02-2.07, p=0.03), HR negative (HR=1.61,95%CI=1.15-2.26,p=0.006), node positivity (HR=1.82,95%CI=1.31-2.53,p&lt;0.01) and ExBx done (HR=1.40,95%CI=0.99-1.98,p=0.053) had a detrimental impact on disease free survival.
Conclusion: ExBx of the primary tumour as a diagnostic procedure not performed with oncological principles prior to definitive surgery has a detrimental impact on survival in women with operable breast cancer.
Citation Format: Nita Sukumar Nair, Rohini W Hawaldar, Quarratulain Chougle, Vani Parmar, Vaibhav Vanmali, Shabina Siddique, Ashwini Devade, Aarti Pandey, Shalaka Joshi, Sudeep Gupta, Rajendra A Badwe. Impact of lumpectomy for diagnosis of primary tumor on disease free survival in women with operable breast cancer: An institutional audit [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P1-20-25.
Abstract P1-20-27: Changes in the shoulder range of motion, strength after breast cancer surgery: An observational study
Authors: Min Jihee , Yeon Sujin , Min Jinjoo , Kim Jee Ye , Kim Seung Il , Park Ha-Nui , Lee Jeong min , Jeon Justin Y. 
Published: March 2020

Abstract
Purpose: The importance of rehabilitation after breast surgery is valued, yet changes in range of motion (ROM) and shoulder strength after surgery have not been elucidated. The aim of this study was to explore the shoulder ROM and strength in both surgery (SS) and non-surgery side (NSS) after breast cancer surgery for up to four weeks.
Methods: Twenty-five patients (7 total mastectomy, 18 partial mastectomy) were observed five times: the day before surgery, on discharge day (post operate day; POD 1 or 2), the 1st outpatient visit (POD 7-10), the 2nd outpatient visit (POD 14-15), and 3rd outpatient visit (POD 21-25). The primary outcomes were ROM and strength of both the SS and NSS.
Results: While ROM declined only in the shoulder of the SS, shoulder strength declined in both SS and NSS. Greatest reduction in shoulder strength was observed in flexion (SS: -43.9% to -45.3%, NSS: -14.2% to -35.8%) and abduction in both SS and NSS (SS: -41.1% to -52.5%, NSS: -16.3% to -30.6%). Shoulder strength on the SS decline immediately after surgery, which remained low after four weeks. Shoulder strength of the NSS continually declined after surgery up to four weeks.
Conclusion:These results provide preliminary evidence for clinicians to understand the changes of shoulder ROM, strength, and function after surgery in breast cancer patients. Rehabilitation exercises should be implemented in both SS and NSS.
Citation Format: Jihee Min, Sujin Yeon, Jinjoo Min, Jee Ye Kim, Seung Il Kim, Ha-Nui Park, Jeong min Lee, Justin Y. Jeon. Changes in the shoulder range of motion, strength after breast cancer surgery: An observational study [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P1-20-27.
Abstract P2-05-07: Pan-cancer analysis of PARP inhibition reveals a suite of biomarkers that correlate with PARP1/2 activity in breast cancer
Authors: McDermott Martina SJ , Conklin Dylan F , O'Brien Neil A , Chau Kevin , Slamon Dennis J 
Published: March 2020

Abstract
The development of multiple PARP inhibitors in BRCA mutant cancers has been one of the most successful implementations of molecularly targeted therapies in oncology. The recent approval of niraparib in BRCA WT Ovarian cancers demonstrates the potential for expansion of PARP inhibitors to other BRCA WT indications. The successful development of PARP inhibitors into new cancer indications will depend on using molecular biomarkers to identify tumors with a unique dependency on PARP1/2 activity. We screened a large (N=523), diverse panel of human cancer cell lines for response to three approved PARP inhibitors: olaparib, niraparib, and talazoparib. Despite differences in relative potency, there was a strong correlation between sensitive and resistant cell lines to all three compounds. In vitro experimentation revealed the inhibitors share a similar biologic mechanism of response, namely a global decrease in PARylation, as well as PARP-trapping at DNA nicks leading to G2 arrest and ultimately cell death. A suite of baseline genomic and proteomic characteristics were found to be strongly associated with response to PARP1/2 inhibition, and were largely consistent between different cancer types. Special attention was paid to BRCA1/2 variants, which represent the only approved patient selection biomarkers. Notably, neither mutations in BRCA1 nor BRCA2 were found to be associated with response to PARP1/2 inhibition in our panel, even when restricting to those with confirmed deleterious ClinVar scores. The molecular predictors of response identified in our screen may ultimately be used to develop diagnostic tools for enrollment into biomarker-enriched clinical trials to expand the use of this promising class of drug into areas of high unmet need. Triple-negative breast cancer represents one of the most intriguing spaces for development. The clinical failures in this space may be partially explained by the lack of empirical predictive biomarkers in the trial design. Our diagnostics may finally allow for the efficacious deployment of PARP inhibitors to triple-negative breast cancer. In particular we have identified a panel of biomarkers that can predict for sensitivity to PARP inhibitors in breast cancer that could be used as patient selection criteria for the expanded clinical development of these compounds into PARP-naïve patient populations with high unmet need.
Citation Format: Martina SJ McDermott, Dylan F Conklin, Neil A O'Brien, Kevin Chau, Dennis J Slamon. Pan-cancer analysis of PARP inhibition reveals a suite of biomarkers that correlate with PARP1/2 activity in breast cancer [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P2-05-07.
Abstract P2-09-08: Breast cancer tumor sequencing coupled with germline genetic testing aids the identification of at-risk individuals for hereditary breast cancer disorders
Authors: Pineda-Alvarez Daniel E , Michalski Scott T , Russell Meaghan , Yang Shan , Song Ihn Young , Nussbaum Robert L , Esplin Edward D. 
Published: March 2020

Abstract
Background: With the rise of precision medicine, hereditary cancer germline testing and tumor genetic testing have been increasingly used to inform the management of patients with cancer. Recent studies report that approximately 10% of patient’s tumors have clinically significant variants in genes known to predispose to a hereditary cancer syndrome. Here we report the concordance rate between tumor genetic testing and germline genetic testing in patients with breast cancer and review its impact on the patients’ management and implications for their relatives.
Methods: In this study, we used de-identified data from 101 consecutive patients with breast cancer who underwent tumor genetic testing followed by germline testing with NGS-based hereditary cancer gene panels.
Results: Tumor genetic testing results included likely pathogenic or pathogenic (LP/P) variants in BRCA2 (21%), BRCA1 (20%), TP53 (10%), CDH1 (7%), ATM (4.3%), PALB2,CHEK2, and PTEN (3.7% each), and PIK3CA (2.5%) among 22 other genes. In 33/101 cases (33%) the P/LP variant was also detected in the germline. Genes in which disease-causing variants were most frequently confirmed to be in the germline included: BRCA2 (36%), BRCA1(21%), PALB2 (12%), and CHEK2 (12%). Variants in ATM, FH, FANCA, and MSH6 were confirmed in the germline in &lt;10% of patients with variants in these genes. Variants in the TP53, CDH1, and PIK3CA genes were detected in the tumor but not in the germline. In 1 case a pathogenic germline variant was detected in the BRIP1 gene but not reported in the tumor, because the gene was not included in the tumor testing panel.
Conclusions: A significant proportion (33%) of patients with clinically significant variants in tumors were identified to carry the same variant in the germline, uncovering a previously unknown risk of hereditary breast cancer disorder. Notably, some genes had a high probability of variants occurring in the germline, while others were primarily seen in tumors. Performing simultaneous germline and tumor testing may inform susceptibility to a hereditary cancer disorder, identify targets for precision therapy, early detection of secondary malignancies, and guide genetic counseling for relatives.
Citation Format: Daniel E Pineda-Alvarez, Scott T Michalski, Meaghan Russell, Shan Yang, Ihn Young Song, Robert L Nussbaum, Edward D. Esplin. Breast cancer tumor sequencing coupled with germline genetic testing aids the identification of at-risk individuals for hereditary breast cancer disorders [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P2-09-08.
Abstract P2-10-11: Participation of African Americans in clinical trials supporting FDA approval of breast cancer medications
Authors: Hadidi Samer Al , Mims Martha , Miller-Chism Courtney , Kamble Rammurti 
Published: March 2020

Abstract
BACKGROUND African Americans comprise 12% of the total United States population. Lifetime probability of developing cancer in African Americans is 37.55%. Lifetime probability of developing breast cancer in African Americans is 11.1%. African Americans have higher lifetime probability of dying because of breast cancer compared to Caucasians (3.3% versus 2.7%). Concerns exist that African Americans are underrepresented in trials of breast cancer medications. We sought to examine African Americans participation for pivotal breast cancer medications trials submitted to the U.S. Food and Drug Administration (FDA) supporting marketing applications. METHODS On the basis of publicly available FDA reviews, the authors assessed enrollment of African Americans in trials supporting 9 drug approvals from 2014 to 2018. Those trials resulted in approval of medications to treat breast cancer. Prevalence-corrected estimates for the participation of African Americans were calculated as the percentage of African Americans among trial participants divided by the percentage of African Americans in the disease population (participation to prevalence ratio [PPR]), with a range between 0.8 and 1.2 reflecting similar representation of African Americans in the trial and disease population. RESULTS A total of 22,075 patients enrolled in clinical trials, which resulted in subsequent FDA approval. The proportion of African Americans enrolled in the clinical trials that led to breast cancer medication approval in the 5-year period was 6.83%. The calculated PPR for participation of African Americans in clinical trials that led to drug approval for breast cancer was 0.29. CONCLUSIONS African Americans were under represented in trials of drugs for breast cancer. Efforts should be made to increase the proportion of participation of African Americans in clinical trials.
Citation Format: Samer Al Hadidi, Martha Mims, Courtney Miller-Chism, Rammurti Kamble. Participation of African Americans in clinical trials supporting FDA approval of breast cancer medications [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P2-10-11.
Abstract P2-12-11: Does goserelin have an effect on quality of life in women who have chemotherapy for early breast cancer? Results from the OPTION randomised trial
Authors: Leonard Robert CF , Mansi Janine , Yellowlees Ann , Fallowfield Lesley , Jenkins Valerie 
Published: March 2020

Abstract
The OPTION trial examined whether or not premenopausal women with early breast cancer receiving chemotherapy benefited from ovarian function protection with goserelin. This trial showed some preservation of ovarian function and fertility in women aged 40 years or less*. Additionally the OPTION trial examined the immediate and late impact of treatments on patients’ Quality of Life (QoL) over a 5 year period. Patients and Methods: In the OPTION trial 227 pre-menopausal patients with early stage breast cancer were randomly assigned to chemotherapy with or without goserelin. Patients were stratified by age into ≤40 years and &gt; 40 years of age. QoL was assessed with the Functional Assessment of Cancer Therapy - Breast (FACT-B) and Endocrine Symptom checklist(ES) at baseline (pre- treatment), 3, 6, 12, 18 and 24 months, then annually to 5 years. Results:-Two hundred and thirteen patients were available for analysis of QoL results. There was a temporary increase in endocrine symptoms of menopause in the goserelin group that was statistically higher than in the controls (P = 0.02) and was associated with a decrease in the main outcome measure of global QoL, TOI. This contrasted with a longer term outcome favouring the intervention in terms of QoL and fewer adverse endocrine symptoms, though these later findings were not statistically significant. Conclusions: Cytotoxic chemotherapy with or without goserelin causes a short term decrement in QoL for up to 6 months in otherwise well women.* Ann Onc 2017 28 1811-1816.
Citation Format: Robert CF Leonard, Janine Mansi, Ann Yellowlees, Lesley Fallowfield, Valerie Jenkins. Does goserelin have an effect on quality of life in women who have chemotherapy for early breast cancer? Results from the OPTION randomised trial [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P2-12-11.
Abstract P2-13-20: Conditional survival of female breast cancer patients by treatment patterns: Evidence from the Korean nationwide registry
Authors: Song Eun Jin , Jung So-Youn , Kim Young Ae , Kong Sun-Young , Lee Eun Sook , Lee Eun-Gyeong , Jo Heein , Han Jae Hong , Lee Seeyoun , Kang Han-Sung 
Published: March 2020

Abstract
Objective: With the development of breast cancer treatment, the prognosis of breast cancer patients is getting better over time. Breast cancer patients want to get accurate information about prognosis according to the treatment pattern. In this study, we investigated the 5-year Conditiona relative survival (CRS) of Korean female breast cancer patients.
Materials and Methods: The data from this study was collected from the Korean Central Cancer Registry (KCCR) data, National Health Insurance Service (NHIS) data and Korean Statistical Information Service (KOSIS) data to certify relative survival and conditional relative survival for the female patients of breast cancer in the Korea. We identified 141,779 female breast cancer cases diagnosed between 2002 and 2013. The CRS was estimated for every year after diagnosis, according to age, stage at diagnosis, histologic type, year at diagnosis and treatment patterns within 1year after diagnosis.
Results: The 5-year RS at diagnosis was 91.0% and the 10-year RS was 85.9%. The 5-year CRS was 91.1% and 94.3% at 1 year and 5 years after diagnosis, respectively. Very young and very old patients had worse 5-year CRS after 5 years of survival than those of other age groups (89.6% in the &lt;40-year and 84.4% in the ≥70-year groups vs. 92.6% in 40-54-year, and 90.3% in 55-69-year groups). Patients who underwent surgery within one year after diagnosis of breast cancer showed better 5-year CRS than those who did not (94.0% vs 65.6%). The 5-year CRS was 91.8% and 89.9% according to whether systemic therapy (chemotherapy and targeted therapy) was performed after diagnosis of breast cancer. The 5-year CRS of the anti-hormone treatment group was 95.2%, which was higher than that of the non-hormone treatment group. In the group without antihormonal therapy, there was a different 5-year CRS according to the histological characteristics (89.8% in NST type, 83.5% in lobular type, 97.3% in mucinous type, 98.5% in medullary type and 86.3% in metaplastic type).
Conclusions: This study shows that the improvement pattern of CRS may vary according to age group, treatment pattern, and histologic type. In the group without antihormone therapy, the histologic type seems to be a different aspect of CRS, which is useful information for clinicians and patients.
Key words: conditional survival, breast cancer, histology, age, stage, treatment pattern
Citation Format: Eun Jin Song, So-Youn Jung, Young Ae Kim, Sun-Young Kong, Eun Sook Lee, Eun-Gyeong Lee, Heein Jo, Jae Hong Han, Seeyoun Lee, Han-Sung Kang. Conditional survival of female breast cancer patients by treatment patterns: Evidence from the Korean nationwide registry [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P2-13-20.
Abstract P2-14-05: Adjuvant chemotherapy in elderly women with triple-negative breast cancer: Swedish registry data 2009-2017
Authors: Janeva Slavica , Zhang Chenyang , Kovács Anikó , Parris Toshima Z , Tzikas Anna-Karin , Pezzi Christopher M , Audisio Riccardo A , Bagge Roger Olofsson 
Published: March 2020

Abstract
Background: Breast cancer incidence is strongly related to age, with the highest incidence rates being in elderly women. Triple-negative breast cancer (TNBC) is an aggressive form of breast cancer associated with worse survival. Due to competing mortality risks and co-morbidities, TNBC in the elderly is often under-treated with adjuvant chemotherapy. The aim of this study was to investigate if there is a gain in both breast cancer specific survival (BCSS) and overall survival (OS) with adjuvant chemotherapy in elderly patients with TNBC.
Method: Information from all patients 70 years and older diagnosed with primary TNBC during the years 2009-2017 were retrieved from the Swedish National Register for Breast Cancer, the Swedish Cause of Death Register and the Swedish Patient Register. Both a propensity score matched (PSM) model and a Cox-regression model was created examining the effect of age, tumor size, tumor grade, nodal status, co-morbidities (Charlson/Deyo) and chemotherapy treatment, on BCSS and OS.
Results: Of the 1421 patients included, 428 (30.1%) received chemotherapy. The 5-year BCSS was 84% vs. 62% in favor for patients receiving chemotherapy. The 5-year OS was 80% vs. 46% in favor for patients receiving chemotherapy. When adjusting for the co-variates using PSM, the 5-year BCSS was 84% vs. 73% (p&lt;0.004) and the 5-year OS was 79% vs. 62% (p&lt;0.001) favoring chemotherapy.
Discussion: In this PSM registry analysis including all patients ≥70 years in Sweden with TNBC during a 9-year period, we could show that there was a significant benefit in both BCSS and OS with adjuvant chemotherapy when adjusting for both age and co-morbidities.
Cox multivariate regression model for breast cancer specific survivalHazard Ratiop-value95% CIChemotherapy0.6020.0020.435-0.834Age (years)1.0510.0001.030-1.072Tumor size (mm)1.0170.0001.012-1.022Stage N11.9090.0001.488-2.450Stage N24.8550.0011.978-11.916Stage N31.9060.5210.266-13.637Grade 21.0140.9790.365-2.813Grade 31.6220.3400.601-4.374Charlson score1.1940.0570.995-1.433
Citation Format: Slavica Janeva, Chenyang Zhang, Anikó Kovács, Toshima Z Parris, Anna-Karin Tzikas, Christopher M Pezzi, Riccardo A Audisio, Roger Olofsson Bagge. Adjuvant chemotherapy in elderly women with triple-negative breast cancer: Swedish registry data 2009-2017 [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P2-14-05.